Innovations in autologous transplantation for hematologic malignancy

Biology of Blood and Marrow Transplantation

Volumn 11, Issue 2 SUPPL. 2, 2005, Pages 28-33

  Forman, Stephen J ^a,b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b Hope Cancer Center   (United States)

Author keywords

Autologous transplantation; Hematologic malignancy

Indexed keywords

CARMUSTINE; CD20 ANTIBODY; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IBRITUMOMAB TIUXETAN; IMATINIB; MELPHALAN; METHOTREXATE; PREDNISONE; THALIDOMIDE; TOSITUMOMAB I 131; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; DRUG MEGADOSE; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LARGE CELL LYMPHOMA; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; MYELODYSPLASIA; NONHODGKIN LYMPHOMA; WHOLE BODY RADIATION;

HEMATOLOGIC NEOPLASMS; HUMANS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 13244277908     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2004.11.014     Document Type: Article

References (56)

1. S.T. Traweek M.L. Slovak N.P. Nademanee et al. Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma Blood 84 1994 957-963
2. R.M. Stone D. Neuberg R. Saiffer et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma J Clin Oncol. 12 1994 2535-2543
3. A. Krishnan S. Bhatia M.L. Slovak et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: An assessment of risk factors Blood 95 2000 1588-1593
4. T. Philip J.O. Armitage G. Spitzer et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma N Engl J Med. 316 1987 1493-1498
5. T. Philip C. Guglielmi A. Hagenbeek et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma N Engl J Med. 333 1995 1540
6. J.O. Armitage Bone marrow transplantation N Engl J Med. 330 1994 827-830
7. A. Nademanee A. Molina A. Dagis et al. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma Clin Lymphoma. 1 2000 46-54
8. J.M. Vose D.J. Rizzo J. Tao-Wu et al. Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission Biol Blood Marrow Transplant. 10 2004 116-127
9. P.J. Stiff S. Dahlberg S.J. Forman et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: Value of augmented preparative regimens - a Southwest Oncology Group trial J Clin Oncol. 16 1998 48-55
10. S.C. Gulati B. Shank P. Black et al. Autologous bone marrow transplantation for patients with poor-prognosis lymphoma J Clin Oncol. 6 1988 1303-1313
11. A. Nademanee G.M. Schmidt M.R. O'Donnell et al. High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: A pilot study Blood 80 1992 1130-1134
12. C. Haioun E. Lepage C. Gisselbrecht et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol - A Groupe d'Etude des Lymphomes de l'Adulte study J Clin Oncol. 18 2000 3025-3030
13. C. Haioun E. Lepage C. Gisselbrecht et al. Groupe d'Etude des Lymphomes de l'Adulte Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: A study of 464 patients J Clin Oncol. 12 1994 2543-2551
14. A.M. Gianni M. Bregni S. Siena et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma N Engl J Med. 336 1997 1290-1297
15. N. Milpied E. Deconinck F. Gaillard et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support N Engl J Med. 350 2004 1287-1295
16. B. Coiffier E. Lepage J. Briere et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med. 346 2002 235-242
17. M. Pfreundschuh L. Trumper M. Kloess et al. 2-Weekly CHOP (CHOP-14): The new standard regimen for patients with aggressive non-Hodgkin's lymphoma (NHL) > 60 years of age Ann Oncol. 13 2002 27
18. O.W. Press J.F. Eary T. Gooley et al. A phase I-II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas Blood 96 2000 2934-2942
19. J. Vose P.J. Bierman J.C. Lynch et al. Radioimmunotherapy with Bexxar combined with high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for refractory non-Hodgkin's lymphoma: Synergistic results with no added toxicity Proc Am Soc Clin Oncol. 20 2001 6a (abstr.)
20. A. Nademanee A. Molina S.J. Forman et al. A phase I-II trial of high-dose radioimmunotherapy with Zevalin in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplant in patients with poor-risk or relapsed B-cell non-Hodgkin's lymphoma Proc Am Soc Hematol. 11 2002 182a (abstr.)
21. M.C. Jensen L.J. Cooper A.M. Wu et al. Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy Cytotherapy 5 2003 131-138
22. A. Molina D. Kraft N. Carter et al. Autologous stem cell transplantation for mantle cell lymphoma: A report of 69 patients from City of Hope and Stanford Proc Am Soc Hematol. 100 2002 182a (abstr.)
23. J.M. Vose P.J. Bierman D.D. Weisenburger et al. Autologous hematopoietic stem cell transplantation for mantle cell lymphoma Biol Blood Marrow Transplant. 6 2000 640-645
24. J. Blade D.H. Vesole M. Gertz Transplantation for multiple myeloma: Who, when, how often? Patient selection and goals Blood 102 2003 3469-3471
25. J. Blade A. Sureda J.M. Ribera et al. High-dose therapy autotransplantation/intensification versus continued conventional chemotherapy in multiple myeloma patients responding to initial chemotherapy: Definitive results from PETHEMA after a median follow-up of 66 months Blood 102 2003 42a (abstr.)
26. M. Attal J.L. Harousseau T. Facon et al. Single versus double autologous stem-cell transplantation for multiple myeloma [erratum appears in N Engl J Med. 2004;350:2628] N Engl J Med. 349 2003 2495-2502
27. M. Cavo P. Tosi E. Zamagni et al. The "Bologna 96" clinical trial of single vs. double autotransplants for previously untreated multiple myeloma patients Blood 100 2002 179a (abstr.)
28. W. Bensinger S. Giralt L. Holmberg et al. 166HO-DOTMP and high-dose melphalan before autologous peripheral blood stem cell transplantation in patients with multiple myeloma Hematol J. 4 2003 S215-S216
29. P.G. Richardson S. Jagannath R. Schlossman et al. A multi-center, randomized, phase 2 study to evaluate the efficacy and safety of 2 CDC-5013 dose regimens when used alone or in combination with dexamethasone (Dex) for the treatment of relapsed or refractory multiple myeloma (MM) Blood 102 2003 235a (abstr.)
30. P.G. Richardson B. Barlogie J. Berenson et al. A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med. 348 2003 2609-2617
31. J. Mehta S. Singhal Graft-versus-myeloma Bone Marrow Transplant. 22 1998 835-843
32. D.G. Maloney F. Sahebi K.E. Stockerl-Goldstein et al. Combining an allogeneic graft-vs-myeloma effect with high-dose autologous stem cell rescue in the treatment of multiple myeloma Blood 98 2001 434a (abstr.)
33. H. Fung A. Nademanee A. Kashyap Evaluation of prognostic factors in patients with Hodgkin's disease in first relapse treated by autologous stem cell transplantation: Duration of first remission does not predict the transplant outcome Blood 90 1997 594a (abstr.)
34. H.M. Lazarus F. Loberiza M.-J. Zhang et al. Autotransplants for Hodgkin's disease in first relapse or second complete remission: A report from the Autologous Blood and Marrow Transplant Registry Proc Am Soc Clin Oncol. 19 2000 49a (abstr.)
35. R. Chopra A.K. McMillan D.C. Linch et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients Blood 81 1993 1137-1145
36. S.J. Horning N.J. Chao R.S. Negrin et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices Blood 89 1997 801-813
37. C. Wheeler C. Eickhoff A. Elias et al. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: A prognostic model for treatment outcomes Biol Blood Marrow Transplant. 3 1997 98
38. Fung HC, Nademanee A, Smith D, et al. A long term follow-up report on autologous hematopoietic stem cell transplantation for 100 consecutive patients with Hodgkin lymphoma in first relapse or second complete remission: Comparisons of two conditioning regimens (total body irradiation based versus BCNU based) and evaluation of prognostic factors. Biol Blood Marrow Transplant. In press
39. P.J. Bierman A. Nademanee Autologous and allogeneic hematopoietic cell transplantation for Hodgkin's disease. In: K.G. Blume S.J. Forman F.R. Appelbaum (Eds.). Thomas' Hematopoietic Cell Transplantation Third Edition 2004 Blackwell Oxford, UK 1191-1207
40. A.M. Carella P. Carlier A. Congiu et al. Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol Bone Marrow Transplant. 8 1991 99
41. A.M. Carella E. Prencipe E. Pungolino et al. Twelve years experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's disease patients in first remission after MOPP/ABVD chemotherapy Leuk Lymphoma. 21 1996 63-70
42. C. Tarella A. Cuttica U. Vitolo et al. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: A multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence Cancer 1 2003 2748-2759
43. H.C. Fung A. Nademanee P. Stiff et al. Intensified cytoreduction with high dose melphalan (HDM) and stem cell rescue (STR) followed by a 2nd high dose therapy (HDT) and autologous stem cell transplant (ASCT) for patients with primary refractory or poor risk recurrent Hodgkin's lymphoma (HD) Blood 96 2000 790a (abstr.)
44. T.T. Hecht D.L. Longo J. Cossman et al. Production and characterization of a monoclonal antibody that binds Reed-Sternberg cells J Immunol. 134 1985 4231-4236
45. M. Slovak K. Kopecky P. Cassileth et al. Karyotypic analysis predicts outcome of preremission therapy in adult acute myeloid leukemia: A South-West Oncology Group/Eastern Cooperative Oncology Group study Blood 96 2002 4075-4083
46. M. Korbling T.M. Fliedner R. Holle et al. Autologous blood stem cell (ABSCT) vs. purged bone marrow transplantation (pABMT) in standard risk AML: Influence of source and cell composition of the autograft on hematopoietic reconstitution and disease-free survival Bone Marrow Transplant 7 1991 343-349
47. A.S. Stein M.R. O'Donnell A. Chai et al. In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission J Clin Oncol. 14 1996 2206-2216
48. A.S. Stein S.J. Forman Autologous hematopoietic cell transplantation for acute myeloid leukemia. In: K.G. Blume S.J. Forman F.R. Appelbaum (Eds.). Thomas' Hematopoietic Cell Transplantation Third Edition 2004 Blackwell Oxford, UK 1221-1237
49. G. Meloni D. Diverio M. Vignetti et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pre-transplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the pm1/rarα fusion gene Blood 90 1997 1321-1325
50. L.C. Feinstein B.M. Sandmaier U. Hegenbart et al. Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission Br J Haematol. 120 2003 281-288
51. J.M. Burke P.C. Caron E.B. Papadopoulos et al. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias Bone Marrow Transplant. 32 2003 549-556
52. A.S. Stein M.R. O'Donnell M.L. Slovak et al. Interleukin-2 following autologous stem cell transplant for adult patients with acute myeloid leukemia in first complete remission J Clin Oncol. 21 2002 615-623
53. T. de Witte S. Suciu G. Verhoef et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS Blood 98 2001 2326-2331
54. S.J. Forman Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults. In: K.G. Blume S.J. Forman F.R. Appelbaum (Eds.). Thomas' Hematopoietic Cell Transplantation Third Edition 2004 Blackwell Oxford, UK 1055-1066
55. X. Thomas J.-M. Boiron F. Huguet et al. Outcome of treatment in adults with acute lymphoblastic leukemia: Analysis of the LALA-94 trial J Clin Oncol. 22 2004 4075-4086
56. I. Avivi J.M. Rowe Acute lymphocytic leukemia: Role of hematopoietic stem cell transplantation in current management Curr Opin Hematol. 10 2003 463-468